The Schall Law Firm is investigating Omeros Corporation for potential securities law violations on behalf of investors. The investigation concerns whether the company issued false or misleading statements or failed to disclose pertinent information. On June 26, 2026, Omeros announced that the CHMP had adopted a negative opinion on its marketing authorization application for narsoplimab in TA-TMA, causing shares to fall more than 19.1% that day. Shareholders who suffered losses are encouraged to contact the firm.
Omeros CorporationCHMP negative opinion on narsoplimab marketing authorization application